HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
First Risk-Adapted Therapy Trial for Newly Diagnosed Patients (the MASTER trial) with Luciano Costa, MD, PhD, UAB
First Risk-Adapted Therapy Trial for Newly Diagnosed Patients (the MASTER trial) with Luciano Costa, MD, PhD, UAB image
HealthTree Podcast for Multiple Myeloma
event Apr 16, 2018 / 11:00AM - 12:00PM MDT

Event Description

Luciano Costa, MD, PhD
University of Alabama at Birmingham
Interview Date: April 16, 2018

Myeloma researchers are learning that the deeper our remissions, the better our outcomes (overall). Dr. Costa joins Myeloma Crowd Radio to share a key study for newly diagnosed multiple myeloma patients that includes four of the best myeloma therapies, a stem cell transplant and then variable maintenance based on the patient's depth of remission. This is one of the first studies ever run in myeloma to give risk-adapted treatment to patients. The study uses a powerful four-drug combination: daratumumab, carfilzomib, lenalidomide and dexamethasone and then stem cell transplant. Following the transplant, patients are tested with a highly sensitive test (MRD test) that can detect one myeloma cell in a million. If patients still have remaining disease, they are given more rounds of the same four-drug combination.

Thanks to our episode sponsor, Celgene Corporation.

Schedule & Agenda

Dr. Luciano Costa & Jenny Ahlstrom

Speakers & Moderators

The panelist Luciano Costa, MD, PhD
Luciano Costa, MD, PhD

Luciano J. Costa, M.D., Ph.D., serves as the Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at UAB. Dr. Costa obtained his M.D. and subsequently Ph.D. from Universidade de Sao Paulo, Brazil. He then trained in hematology and medical oncology at the University of Colorado in Aurora and in blood and marrow transplantation at the Mayo Clinic in Rochester, Minnesota. Prior to joining UAB, Dr. Costa was an Associate Professor of Medicine at the Medical University of South Carolina where he co-chaired the Protocol Review Committee at Hollings Cancer Center. He was recruited to the O’Neal Comprehensive Cancer Center in 2014 as a Senior Clinical Investigator and currently directs the Multiple Myeloma and the Immune Effector Cellular Therapy programs. His primary research focus is the development of new therapies for plasma cell malignancies. Dr. Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma. He is regarded as an international leader in the field with more than 200 peer-reviewed abstracts and publications in high-impact journals such as Blood, Leukemia, the Journal of Clinical Oncology and The New England Journal of Medicine.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube